A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis
GG Krueger, KA Papp, DB Stough, KH Loven… - Journal of the American …, 2002 - Elsevier
Background: In previous phase II studies, alefacept significantly improved psoriasis and was
well tolerated. The clinical response to alefacept was durable. Objective: Our purpose was to
further evaluate efficacy and tolerability of alefacept in a phase III study of patients (n= 553)
with chronic plaque psoriasis. Methods: Two 12-week courses of once-weekly intravenous
alefacept 7.5 mg or placebo were given in a randomized double-blind study; patients were
followed up for 12 weeks after each course. Results: During treatment and follow-up of …
well tolerated. The clinical response to alefacept was durable. Objective: Our purpose was to
further evaluate efficacy and tolerability of alefacept in a phase III study of patients (n= 553)
with chronic plaque psoriasis. Methods: Two 12-week courses of once-weekly intravenous
alefacept 7.5 mg or placebo were given in a randomized double-blind study; patients were
followed up for 12 weeks after each course. Results: During treatment and follow-up of …